- Home
- BCDA vs HIHO Comparison
BCDA vs HIHO Comparison
Compare BCDA & HIHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- HIHO
- Stock Information
- Founded
- BCDA N/A
- HIHO 1990
- Country
- BCDA United States
- HIHO Hong Kong
- Employees
- BCDA N/A
- HIHO N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- HIHO Industrial Machinery/Components
- Sector
- BCDA Health Care
- HIHO Industrials
- Exchange
- BCDA Nasdaq
- HIHO Nasdaq
- Market Cap
- BCDA 7.9M
- HIHO 8.2M
- IPO Year
- BCDA N/A
- HIHO 1996
- Fundamental
- Price
- BCDA $2.68
- HIHO $1.96
- Analyst Decision
- BCDA Strong Buy
- HIHO
- Analyst Count
- BCDA 1
- HIHO 0
- Target Price
- BCDA $25.00
- HIHO N/A
- AVG Volume (30 Days)
- BCDA 73.1K
- HIHO 8.5K
- Earning Date
- BCDA 11-06-2024
- HIHO 10-10-2024
- Dividend Yield
- BCDA N/A
- HIHO 3.59%
- EPS Growth
- BCDA N/A
- HIHO N/A
- EPS
- BCDA N/A
- HIHO N/A
- Revenue
- BCDA $428,000.00
- HIHO $7,648,000.00
- Revenue This Year
- BCDA $6.92
- HIHO N/A
- Revenue Next Year
- BCDA N/A
- HIHO N/A
- P/E Ratio
- BCDA N/A
- HIHO N/A
- Revenue Growth
- BCDA 0.71
- HIHO 10.41
- 52 Week Low
- BCDA $1.96
- HIHO $1.70
- 52 Week High
- BCDA $23.25
- HIHO $2.36
- Technical
- Relative Strength Index (RSI)
- BCDA 49.01
- HIHO 59.79
- Support Level
- BCDA $2.39
- HIHO $1.92
- Resistance Level
- BCDA $2.90
- HIHO $2.00
- Average True Range (ATR)
- BCDA 0.18
- HIHO 0.07
- MACD
- BCDA -0.00
- HIHO 0.01
- Stochastic Oscillator
- BCDA 53.70
- HIHO 80.95
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About HIHO Highway Holdings Limited
Highway Holdings Ltd is a holding company. The company is a manufacturer of metal, plastic, electric and electronic components for original equipment manufacturers (OEM) and contract manufacturers. Its operating segment includes Metal stamping and mechanical OEM and Electric OEM. The metal stamping segment focuses on the manufacturing and sale of metal parts and components. The company generates maximum revenue from the Metal stamping and mechanical OEM segment. Geographically, it derives a majority of its revenue from Europe and also has a presence in Hong Kong and China, North America, and Other Asian countries.